Related Party Transactions

12 Months Ended

Dec. 31, 2023

Related Party Transactions [Abstract]

Related Party Transactions

NOTE 19. Related Party Transactions

Significant Stockholders

Prior to the IPO, the Company maintained a consulting agreement with CD&R, for which it paid advisory consulting fees on a quarterly basis. For the years ended December 31, 2023, 2022 and 2021, the Company paid $0.1 million, $0.2 million and $0.8 million, respectively, to CD&R in advisory consulting fees, in addition to certain expense reimbursements. These are recorded in general and administrative expense in the accompanying consolidated statements of operations. In connection with the IPO, the Company and CD&R terminated the consulting agreement, effective April 16, 2021. The Company was not charged a fee in connection with the termination of this agreement. During the years ended December 31, 2023 and 2021, the Company recognized general and administrative expenses of $1.7 million and $2.8 million, respectively, to administered secondary offerings of shares of its common stock sold by CD&R and did not receive any proceeds from any sale of shares of its common stock.

Unsecured Debt

See Note 10 for details on the issuance of unsecured debt to a fund affiliated with CD&R.

Equity Method Investments

For the years ended December 31, 2023, 2022, and 2021, the Company incurred expenses of $8.9 million, $9.6 million, and $8.4 million, respectively for provider services delivered by Population Health, LLC, which is accounted for under the equity method based on a 49% equity ownership interest held by the Company. As of December 31, 2023 and 2022, the Company had an outstanding payable to Population Health, LLC of $1.5 million and $1.2 million, respectively.

For the years ended December 31, 2023, 2022, and 2021, the Company recognized income of $1.6 million, $1.6 million, and $0.7 million, respectively, for technology services rendered to the ACOs. The Company is reimbursed for certain expenses paid on behalf of the ACOs. As of December 31, 2023 and 2022, the Company had an outstanding receivable from the ACOs of $6.3 million and $6.9 million, respectively.